Santhera Pharmaceuticals AG (SANN.SW) and Ipsen Renegotiate Fipamezole Licensing Agreement  
1/24/2012 6:02:17 AM

LIESTAL, Switzerland & PARIS--(BUSINESS WIRE)--Regulatory News:

Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) announced today that they had renegotiated their fipamezole licensing agreement. Santhera regains the worldwide rights to the development and commercialization of fipamezole, its first-in-class selective adrenergic alpha-2 receptor antagonist for the management of levodopa-induced Dyskinesia in Parkinson’s Disease. Under the renegotiated terms, Ipsen returns its rights for territories outside of North America and Japan in exchange for milestone payments and royalties based on future partnering and commercial success of fipamezole. Ipsen retains a call option for worldwide license to the program under certain conditions.